The Medicaid Services Investment and Accountability Act of 2019 (the Act) became law on April 18, 2019. Of most relevance to pharmaceutical manufacturers are the provisions amending the Medicaid statute concerning the Medicaid Drug Rebate Program (MDRP).
The US Department of Justice (DOJ) recently announced charges in a billion-dollar health care fraud scheme involving telemedicine and the provision of allegedly unnecessary durable medical equipment (DME) to Medicare beneficiaries.
The Massachusetts Department of Family and Medical Leave recently released an implementation timeline for the new paid family and medical leave program, revised draft regulations, and a series of “toolkits” to assist employers and workers with their preparations for the new benefit.
On March 28, 2019 CMS issued the Final Rule and Interim Final Rule with Comment Period: Medicaid Program; Covered Outpatient Drug; Finalization of Line Extension Definition; and Change to the Rebate Calculation for Line Extension Drugs.
In a groundbreaking decision, the Occupational Safety and Health Review Commission on March 4, 2019 ruled for the first time that the Occupational Safety and Health Act’s (OSH Act) general duty clause obligates employers to protect their workers from workplace violence.
After announcing in December that it would intervene in a qui tam action under the False Claims Act against Sutter Health and Palo Alto Medical Foundation (PAMF), the US Department of Justice filed its complaint-in-intervention in the Northern District of California on March 4, 2019.
Health Care Partner Douglas Grimm and Associate Hillary Stemple authored an article for the March 2019 edition of Compliance Today titled “Telemedicine: A review of the fraud and abuse landscape.”
Health Care Partner Douglas Grimm and Associate Hillary Stemple authored an article for the March 2019 edition of Compliance Today titled “Telemedicine: A review of the fraud and abuse landscape.”
On February 19, 2019, the Supreme Court of the United States denied a request from Maryland’s Attorney General to review the decision of the Fourth Circuit Court of Appeals, which held the state’s drug price gouging law to be unconstitutional.
Massachusetts moved one step closer to establishing a paid family and medical leave program with the recent release of draft regulations by the newly formed Department of Family and Medical Leave (the “Department”).